Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Sofia Miranda-Pasqualini

Nurse Practitioner, Family Deerfield Beach, FL Nurse Practitioner

NPI 1235799727 CMS profile 10941603

1500 E Hillsboro Blvd Ste 207, Deerfield Beach, FL 33441

Open in the dashboard

General payments

$21,532

461 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sofia Miranda-Pasqualini of Deerfield Beach, FL is reported in the CMS Open Payments database as having received $21,532 across 461 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,795 34
2024 General $3,150 137
2023 General $6,127 217
2022 General $1,011 43
2021 General $1,449 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sofia Miranda-Pasqualini
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Sofia Miranda-Pasqualini were reported at $9,795. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Sofia Miranda-Pasqualini Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,449 $124 $35–$379 $132
2022 $1,011 $141 $44–$430 $149
2023 $6,127 $154 $49–$476 $160
2024 $3,150 $165 $51–$504 $164
2025 $9,795 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Genzyme Corporation $9,149 16 payments
  2. UCB, Inc. $1,084 34 payments
  3. LivaNova USA, Inc. $994 4 payments
  4. EMD Serono, Inc. $953 26 payments
  5. AbbVie, Inc. $907 46 payments
  6. Eli Lilly and Company $900 1 payment
  7. US WorldMeds, LLC $664 16 payments
  8. Lilly USA, LLC $630 16 payments
  9. Teva Pharmaceuticals USA, Inc. $454 17 payments
  10. Pfizer Inc. $452 21 payments
  11. Other $5,346 264 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,842 448 payments
  2. Consulting Fee $5,858 2 payments
  3. Travel and Lodging $2,928 9 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $900 1 payment
  5. Education $4 1 payment
Products named General payments · program years 2021–2025
  1. QFITLIA $4,954 5 payments
  2. ALTUVIIIO $4,100 7 payments
  3. VNS Therapy $994 4 payments
  4. Apokyn $573 11 payments
  5. Austedo XR $454 17 payments
  6. ZTLido $340 27 payments
  7. AMYVID $331 10 payments
  8. MAVENCLAD $327 17 payments
  9. Briviact $326 12 payments
  10. UBRELVY $288 13 payments
  11. Other $8,593 384 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

689

Median for Nurse Practitioner: 389

Drug cost

$507,404

Median for Nurse Practitioner: $21,885

Branded share of claims

25%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 49 $390,191
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 13 $93,702
Emgality Pen Galcanezumab-Gnlm Brand 18 $12,238
Memantine Hcl Generic 79 $3,027
Gabapentin Generic 108 $1,648
Donepezil Hcl Generic 116 $1,068
Carbidopa-Levodopa Carbidopa/Levodopa Brand 49 $1,033
Primidone Generic 36 $1,004
Levetiracetam Generic 27 $912
Quetiapine Fumarate Generic 31 $866

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$50,393

Of which drugs: $5,977

Medicare patients

379

Average age 79

Services billed

2,002

225 women, 154 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 73%
Ischemic heart disease 51%
Depression 40%
Diabetes 33%
Alzheimer's or dementia 29%
Chronic kidney disease 28%
Osteoporosis 28%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 17 139 $13

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Apokyn
  • US WorldMeds, LLC $573
$573 — —
ZTLido
  • Scilex Pharmaceuticals Inc. $312
$312 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $165
$165 — —
HYQVIA
  • Takeda Pharmaceuticals U.S.A., Inc. $157
$157 — —
Briviact
  • UCB, Inc. $143
$143 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

461 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record